Klas G. Wiman

This study shows that combining APR-246 and Novobiocin synergistically kills TP53-mutant AML cells through p53-dependent and -independent mechanisms, with low toxicity.

This paper develops a mouse model with a TP53 nonsense mutation to study tumor development and finds it leads to frequent multicentric or metastatic tumors.

This study shows that combining palbociclib and crizotinib enhances senescence and immune recognition in melanoma cells regardless of BRAF/NRAS status, reducing tumor growth.